7827 — HanchorBio Share Price
Last trade - 00:00- TWD22.34bn
- TWD21.73bn
- TWD312.22m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 52.07 | ||
| Price to Tang. Book | 52.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 71.54 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.27% | ||
| Return on Equity | -83.84% | ||
| Operating Margin | -117.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | n/a | 3.36 | n/a | n/a | 312.22 | n/a | n/a | 352.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HanchorBio Inc. is a Cayman Islands-based clinical-stage biotechnology company. The Company is developing immunotherapies for oncology and autoimmune diseases. It develops biological medicines with simultaneous multi-targeting through a novel IGG FC-Based Designer Biologics (FBDB) platform. The Company's pipeline includes HCB101, HCB301, HCB303, HCB302, SIRPa x anti-CCC FBDB, IL-X FBDB, IL-Y FBDB, and IL-Z FBDB. Its HCB101 is a differentiated (engineered) SIRPa-Fc fusion protein targeting CD47-SIRPa signaling pathway, in patients with advanced solid tumors or relapsed/refractory (R/R) non-Hodgkin lymphomas (NHLs).
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- November 11th, 2020
- Public Since
- June 20th, 2025
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 139,605,737
- Address
- Suite 102, Cannon Place, North Sound Rd, GEORGE TOWN, KY1-9006
- Web
- https://www.hanchorbio.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 7827
Similar to 7827
Abnova Taiwan
Taiwan Stock Exchange
Applied BioCode
Taiwan Stock Exchange
Energenesis Biomedical Co
Taiwan Stock Exchange
Genomics Bioscience & Technology Co
Taiwan Stock Exchange
Kim Forest Enterprise Co
Taiwan Stock Exchange
FAQ
As of Today at 21:02 UTC, shares in HanchorBio are trading at TWD160.00. This share price information is delayed by 15 minutes.
Shares in HanchorBio last closed at TWD160.00 and the price had moved by over the past 365 days. In terms of relative price strength the HanchorBio share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreHanchorBio does not currently pay a dividend.
HanchorBio does not currently pay a dividend.
HanchorBio does not currently pay a dividend.
To buy shares in HanchorBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD160.00, shares in HanchorBio had a market capitalisation of TWD22.34bn.
Here are the trading details for HanchorBio:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 7827
Based on an overall assessment of its quality, value and momentum HanchorBio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HanchorBio. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +34.14%.
As of the last closing price of TWD160.00, shares in HanchorBio were trading +47.54% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HanchorBio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD160.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on HanchorBio's directors